Literature DB >> 9657787

Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study.

R M Martin1, K V Kapoor, L V Wilton, R D Mann.   

Abstract

Mesh：

Year:  1998        PMID： 9657787      PMCID： PMC28603          DOI： 10.1136/bmj.317.7151.119

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Review of yellow cards--1986 and 1987.

Authors:  J L Bem; R D Mann; M D Rawlins
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-07

2.  Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom.

Authors:  K J Belton; S C Lewis; S Payne; M D Rawlins; S M Wood
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

3.  United Kingdom Product Licence applications involving new active substances, 1987-1989: their fate after appeals.

Authors:  M D Rawlins; D B Jefferys
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335
  3 in total
  48 in total

Review 1.  What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world.

Authors:  Rohini B M Fernandopulle; Krisantha Weerasuriya
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.

Authors:  Deborah Layton; Vicki Osborne; Anna Gilchrist; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

Review 3.  Advances in targeted therapy: safety of biological agents.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  Paediatric postmarketing pharmacovigilance using prescription-event monitoring: comparison of the adverse event profiles of lamotrigine prescribed to children and adults in England.

Authors:  Beate Aurich-Barrera; Lynda Wilton; David Brown; Saad Shakir
Journal:  Drug Saf       Date:  2010-09-01       Impact factor: 5.606

5.  Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Andrew Boshier; Victoria Cornelius; Scott Harris; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Influence of pharmacists' attitudes on adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; J J Gestal-Otero
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

7.  An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.

Authors:  Andrea Clarke; Jonathan J Deeks; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.

Authors:  Richard C Clark; Simon R J Maxwell; Sheena Kerr; Melinda Cuthbert; Duncan Buchanan; Doug Steinke; David J Webb; Nicholas D Bateman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.

Authors:  Marjolein J C Willemen; Aukje K Mantel-Teeuwisse; Yvonne Buggy; Deborah Layton; Sabine M J M Straus; Hubert G M Leufkens; Toine C G Egberts
Journal:  Drug Saf       Date:  2012-12-01       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.